Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Pamela Arcella
Institution:
Candiolo Cancer Institute
Observed institutions:
Candiolo Cancer Institute,
University of Turin
ORCID:
0000-0002-8695-9196
Observed ORCID:
0000-0002-8695-9196
OpenAlex ID:
A5088902807
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
2020
·
Vito Amodio
, Rona Yaeger
, et al.
·
Cancer Discovery
·
537
PDF
Basic principles of biobanking: from biological samples to precision medicine for patients
2021
·
Laura Annaratone
, Giuseppe De Palma
, et al.
·
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
·
275
PDF
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer
2018
·
Giulia Siravegna
, Luca Lazzari
, et al.
·
Cancer Cell
·
165
PDF
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
2019
·
Sabrina Arena
, Giorgio Corti
, et al.
·
Clinical Cancer Research
·
119
PDF
Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer
2019
·
Luca Lazzari
, Giorgio Corti
, et al.
·
Clinical Cancer Research
·
81
PDF
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer
2020
·
Annalisa Lorenzato
, Alessandro Magrì
, et al.
·
Cancers
·
79
PDF
Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids
2021
·
Gianluca Mauri
, Erika Durinikova
, et al.
·
JCO Precision Oncology
·
23
PDF
Abstract 2848: Radiographic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer
2018
·
Giulia Siravegna
, Luca Lazzari
, et al.
·
Cancer Research
·
1
PDF
Genome-wide biomarker analysis across the full spectrum of HER2-expressing breast cancers to reveal a clonal chromosome 17 imbalance defining unfavourable HER2-low disease
2026
·
Sara Erika Bellomo
, Enrico Berrino
, et al.
·
Biomarker Research
Data from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
2023
·
Vito Amodio
, Rona Yaeger
, et al.
Supplementary Figure 2 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
2023
·
Vito Amodio
, Rona Yaeger
, et al.
PDF
Supplementary Table 2 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
2023
·
Vito Amodio
, Rona Yaeger
, et al.
Supplementary Figure 3 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
2023
·
Vito Amodio
, Rona Yaeger
, et al.
PDF
Supplementary Figure 4 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
2023
·
Vito Amodio
, Rona Yaeger
, et al.
PDF
Supplementary Table 1 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
2023
·
Vito Amodio
, Rona Yaeger
, et al.
Supplementary Table 3 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
2023
·
Vito Amodio
, Rona Yaeger
, et al.
Supplementary Figure 1 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
2023
·
Vito Amodio
, Rona Yaeger
, et al.
Supplementary Table 2 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
2023
·
Vito Amodio
, Rona Yaeger
, et al.
Data from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
2023
·
Vito Amodio
, Rona Yaeger
, et al.
Supplementary Table S2 from Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer
2023
·
Luca Lazzari
, Giorgio Corti
, et al.
Supplementary Table S1 from Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer
2023
·
Luca Lazzari
, Giorgio Corti
, et al.
Supplementary Table S3 from Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer
2023
·
Luca Lazzari
, Giorgio Corti
, et al.
Supplementary Table S4 from Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer
2023
·
Luca Lazzari
, Giorgio Corti
, et al.
Supplementary Data from Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer
2023
·
Luca Lazzari
, Giorgio Corti
, et al.
Supplementary Table S1 from Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer
2023
·
Luca Lazzari
, Giorgio Corti
, et al.
Show more works
View as search
Works count:
41
Citation count:
1,280
H-index:
7
I10-index:
7
Year
Topic
Type